Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms KINECT; KINECT-1
  • Sponsors Neurocrine Biosciences

Most Recent Events

  • 01 Nov 2021 According to a Neurocrine Biosciences media release, results of new pooled analysis from the KINECT clinical trial program and long-term extension studies presented at the 2021 Psych Congress scientific meeting
  • 01 Nov 2021 Results published in the Neurocrine Biosciences Media Release
  • 27 Apr 2018 Results of a pooled analysis from KINECT, KINECT 2, and KINECT 3 studies assessing minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score in tardive dyskinesia, presented at the 70th Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top